Notification That Annual Report Will Be Submitted Late (nt 10-k)

Date : 04/01/2019 @ 10:19PM
Source : Edgar (US Regulatory)
Stock : InventaBioTech Inc. (INVB)
Quote : 0.0255  0.0 (0.00%) @ 1:23PM

Notification That Annual Report Will Be Submitted Late (nt 10-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

OMB APPROVAL
OMB Number: 3235-0058
Expires: February 28, 2022
Estimated average burden hours per response ... 2.50
 
SEC FILE NUMBER
000-53030
 
CUSIP NUMBER
 

 

(Check one):   x Form 10-K ¨   Form 20-F ¨   Form 11-K  ¨   Form 10-Q ¨   Form 10-D ¨   Form N-SAR ¨   Form N-CSR
     
    For Period Ended:   December 31, 2018
     
    ¨    Transition Report on Form 10-K
     
    ¨    Transition Report on Form 20-F
     
    ¨    Transition Report on Form 11-K
     
    ¨    Transition Report on Form 10-Q
     
    ¨    Transition Report on Form N-SAR
     
    For the Transition Period Ended:

 

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

InventaBioTech Inc.
Full Name of Registrant

 

 
Former Name if Applicable

 

3463 Magic Drive, Suite 120
Address of Principal Executive Office  (Street and Number)
 

 

San Antonio, TX 78229
City, State and Zip Code

 

 

     
 

 

 

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

x (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
   
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
   
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

INVENTABIOTECH INC. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2018 (the “Annual Report”) by the April 1, 2019 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. As a result, the Registrant is still in the process of compiling required information to complete the Annual Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the period ended December 31, 2018 to be incorporated in the Annual Report. At this time, the Registrant cannot estimate when it will file the Annual Report.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

  Steven W. Charest   (210)   767-2727
  (Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
  Yes ý No ¨
   
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
  Yes ¨ No ý
   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

     
 

 

INVENTABIOTECH INC.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 1, 2019 By: /s/ Steven W. Charest
  Name:  Steven W. Charest
  Title:  Chief Executive Officer

 

 
 

 

 

 

     
 

 

InventaBioTech Inc. (USOTC:INVB)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more InventaBioTech Inc. Charts.

InventaBioTech Inc. (USOTC:INVB)
Intraday Stock Chart

Today : Sunday 21 July 2019

Click Here for more InventaBioTech Inc. Charts.

Latest INVB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.